Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: 7 - The Real Truth

Democratic candidate compares Florida to ‘Handmaid’s Tale’ in attack on DeSantis

1985 dystopian novel has become shorthand critique of many Republican policies

The Independent UK

New this week: 'The Handmaid’s Tale' and 'Goodnight Mommy'

This week’s new entertainment releases include albums from Little Big Town and Marcus Mumford, “The Handmaid’s Tale” returns with high stakes for the future of Gilead, and twin brothers go to their mother’s house for a stay but find something is off about her in the film “Goodnight Mommy.”

The Independent UK

Television Q&A: What has David Duchovny been up to in recent years?

You have questions. I have some answers.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Everest Medicines Descends To New Depths On String Of Bad News

Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue source after transferring rights for one of its core products to another company By Emily Chan

Benzinga

Limited funding hampers charities’ early monkeypox response

Two biopharmaceutical companies will give $5 million and $500,000, respectively, to nonprofit organizations in the United States and abroad that are responding to the growing monkeypox outbreak

The Independent UK

The Handmaid’s Tale S5 Trailer Shows The Chilling Repercussions After Brutal S4 Finale

Shit's about to get real.

Pedestrian.tv

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

1 Biotech Stock Investors Will Want to Buy This Week

Gilead Sciences (GILD), a biopharmaceutical company, reported strong demand across its HIV portfolio and raised its full-year guidance. Given the company’s robust profitability and discounted valuation, we think it could be wise to buy the stock now. Read on….

StockNews.com

Drugmaker Gilead to help fund monkeypox education for LGBTQ+ groups

Drugmaker Gilead Sciences plans to announce on Tuesday that it will provide up to $5 million in grants to help a coalition of LGBTQ+ and human rights advocacy groups craft public health responses to monkeypox outbreaks, the company said.

Reuters

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

The GOP's "Gilead Playbook"

We're now living in the aftermath of all that the Trump years unleashed. How do we escape this misogynist madness?

Salon

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Margaret Atwood defends ‘I told you so’ mug likening post-Roe America to Handmaid’s Tale

‘The Handmaid’s Tale’ imagines a future in which the US has become a fundamentalist, authoritarian, theocratic regime known as Gilead

The Independent UK

As drugmakers cut off discounts, providers fret for low-income patients

Hospitals and community and rural health clinics that serve low-income patients say drug manufacturers have threatened their financial stability by dramatically cutting back their participation in a federal drug discount program that saves those health providers millions of dollars a year.

Tribune News Service

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

Benzinga

Traders See Bumpy Road Ahead For Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.

Benzinga

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

The Conversation

Fiction about abortion confronts the complicated history of gender, sexuality and women’s rights

Recent debates around Roe v. Wade in the United States have sparked new conversations about the right to abortion and what it means.

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Record

Devastated woman diagnosed with cancer when she was six months pregnant - and now it's incurable

Louise Swain-Hughes, 34, was diagnosed with cancer when she was six months pregnant and is now campaigning for a life-extending drug to be made available on NHS so she can spend more precious time with her son.

Benzinga

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Benzinga

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients

The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection. This approval…

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies

The FDA has

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.